葵花药业：复方聚乙二醇电解质散获药品注册证书

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a new medication aimed at treating chronic constipation in children aged 1 to 11 years old, as well as fecal impaction in children aged 5 to 11 years old [1] Group 1 - The drug, a compound polyethylene glycol (3350) electrolyte solution, is specifically designed for pediatric use [1] - The approval indicates a potential expansion in the company's product offerings within the pediatric healthcare market [1]